All aminoglycosides are produced by soil actinomycetes. All are bactericidal and
        more active at alkaline pH.
    
    The amoniglycosides are bactericidal antibiotics all having same properties.
    
        - Transport of the aminoglycosides through the bacterial cell wall and cytoplasmic
            membrane
- Binding to ribosome resulting in inhibition of protein synthesis. 
- The cidal action is based on secondary changes in the integrity of bacterial cell
            membrane .
        - Avoid during pregnancy.
- Avoid concurrent use of other ototoxic, nephrotoxic drugs.
- Cautious use in patients past middle age and those with kidney damage.
- Cautious use of muscle relaxants in patients receiving aminoglycosides. 
- Do not mix any other drug with aminoglycoside in the same syringe. 
        - Ototoxicity.
- Nephrotoxicity.
- Neuromuscular blockade.
Commercial name: S 0.75gm, 1gm vial.
    
    
        - Tuberculosis.
- Sub-acute bacterial endocarditis.
- Plague.
- Tulareamia.
        - Topical use is contraindicated for fear of contact sensitization.
        - Rashes, eosinophilia, fever and exfoliative dermatitis are noticed.
- Hypersensitivity is rare.
- Pain at injection site.
- Paraesthsia and scotoma are occasional.
        Commercial name: Garamycin, Gentasporin, Genticyn 20,60, 80, 240 mg/vial inj; also
        0.3% eye/ ear drops, 0.1 % skin cream.
    
    
    
        - Preventing and treating respiratory infections in critically ill patients, in those
            with impaired host defence.
- Pseudomonas, Proteus or Klebsiella infections in critically ill patients.
- Meningitis caused by gram-ve bacilli. 
- Dosage: For average adult with normal renal clearance 3-5mg/kg/day I.M. either single
            dose or divided in 3 or 8 hourly doses. 
        - Risk of toxicity is greater with impaired renal function, high dosage or prolonged
            therapy.
- Avoid concurrent and/or sequential topical and /or systematic use of other potential
            neurotoxic and/or nephrotoxic drugs. 
- W/P: Nueromuscular blockade, respiratory paralysis, ototoxicity and nephrotoxicity
            may occur.
        Commercial name: Tobacin 20, 60, 80mg in 2ml inj; 0.3% eye drops, Tobraneg 
        20, 40, 80mg per 2ml vial inj.
    
    
    
        - Serious infections caused by Pseudomonas and Proteus. 
        - Caution with muscular disorders and renal, auditory, vestibular or neuromuscular
            disorders. 
        - Voice alteration, taste perversion and tinnitus.